Skip to main content

Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm discusses Abstract 0402 presented at ACR22 Convergen

Social Author Name
Dr. John Cush
Tweet Content
Opioids and Health Care Utilization in PsA and AS Dr Aurelie Najm discusses Abstract 0402 presented at ACR22 Convergence in Philadelphia, PA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS https://t.co/GsTwHbXVLm https://t.co/22i3yskUpA

Join us on 3/18 and 3/19 in Dallas, Texas or virtually for RheumNow Live! RheumNow Live is unlike any meeting you've ev

Social Author Name
Dr. John Cush
Tweet Content
Join us on 3/18 and 3/19 in Dallas, Texas or virtually for RheumNow Live! RheumNow Live is unlike any meeting you've ever attended. Here's why: -Inspired Education -The Audience Matters -Never Seen Before https://t.co/ezYnhgpJol https://t.co/YWLB4CLuzr

Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation A Longitudinal Swedish study has shown that elev

Social Author Name
Dr. John Cush
Tweet Content
Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib). https://t.co/C3D0fbCEjE https://t.co/70CXgwVFAH
New Guideline: Vaccinations OK With Few Tweaks for Rheum Patients

Nearly all available vaccines can be given to people with rheumatologic diseases, according to a new, detailed guideline from the American College of Rheumatology (ACR), though the timing for their administration and dosing of antirheumatic drugs may need adjustment in some cases.

Only live attenuated-virus vaccines were considered inappropriate for certain patients, namely those taking immunosuppressive drugs that would be risky to withhold, concluded an ACR panel led by Anne R. Bass, MD, of the Hospital for Special Surgery in New York City.

Worldwide prevalence (major markets) of #RA was 4.9 million in 2020; the RA global treatment market is estimated at US $

Social Author Name
Dr. John Cush
Tweet Content
Worldwide prevalence (major markets) of #RA was 4.9 million in 2020; the RA global treatment market is estimated at US $40.5 billion in 2021, and is expected to grow ~6% per year in the next decade. https://t.co/EtBQwru0uF https://t.co/BRLtnwxc2b

Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trau

Social Author Name
Dr. John Cush
Tweet Content
Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/9NjlIExl8c https://t.co/vaRJjwOu2q

Enthesitis portends worse SpA. Data from 749 SpA pts in REGISPONSER-AS registry found 6.1% w/achilles tendinitis at base

Social Author Name
Dr. John Cush
Tweet Content
Enthesitis portends worse SpA. Data from 749 SpA pts in REGISPONSER-AS registry found 6.1% w/achilles tendinitis at baseline. Pts w/ enthesitis had worse pain, BASDAI, mBASDAI, ASDAS-CRP scores & after 2 yrs had fewer in low dz state (16 vs 31.5%) https://t.co/sChQ4WFmlW https://t.co/BkjzxCQIGF

RA Disease Activity and Alcohol Use The effects of alcohol use in RA is less known, but a study suggests that alcohol

Social Author Name
Dr. John Cush
Tweet Content
RA Disease Activity and Alcohol Use The effects of alcohol use in RA is less known, but a study suggests that alcohol consumption was dose-dependently associated with lower disease activity and higher health-related quality of life in RA patients. https://t.co/u6ZjZ7o1Hq https://t.co/S9JPXMJVZo
Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation

A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib). 

AR882, selective uric acid transporter 1 (URAT1) inhibitor in development, completed a phase 2, 140 pt 12-week PBO contr

Social Author Name
Dr. John Cush
Tweet Content
AR882, selective uric acid transporter 1 (URAT1) inhibitor in development, completed a phase 2, 140 pt 12-week PBO controlled trial, where 75 mg/d lowered SUA by 59% (8.6 to 3.5 ) & 42% (8.6 to 5.0 ) in 50 mg dose group - all better than PBO https://t.co/HHzHWj4XQr https://t.co/gJD9hnkFJc
Subscribe to
×